PMID- 28716024
OWN - NLM
STAT- MEDLINE
DCOM- 20180413
LR  - 20220408
IS  - 1476-4598 (Electronic)
IS  - 1476-4598 (Linking)
VI  - 16
IP  - 1
DP  - 2017 Jul 17
TI  - MiR-661 promotes tumor invasion and metastasis by directly inhibiting RB1 in non 
      small cell lung cancer.
PG  - 122
LID - 10.1186/s12943-017-0698-4 [doi]
LID - 122
AB  - BACKGROUND: Aberrant microRNA expression has been implicated in metastasis of 
      cancers. MiR-661 accelerates proliferation and invasion of breast cancer and 
      ovarian cancer, while impedes that of glioma. Its role in non small cell lung 
      cancer (NSCLC) and underlying mechanism are worthy elucidation. METHODS: 
      Expression of miR-661 was measured with real-time PCR in both NSCLC tissues and 
      cell lines. The effects of miR-661 on migration, invasion and metastasis capacity 
      of NSCLC were evaluated using wound healing, transwell assay and animal models. 
      Dual reporter luciferase assay and complementary experiments were performed to 
      validate RB1 as a direct target of miR-661 for participation in the progression 
      of NSCLC. RESULTS: MiR-661 was upregulated in NSCLC tissues as compared to paired 
      adjacent tissues and associated with shorter overall survival. Furthermore, 
      miR-661 promoted proliferation, migration and metastasis of NSCLC. Then, we 
      identified RB1 as a direct target of miR-661 through which miR-661 affected EMT 
      process and metastasis of NSCLC. RB1 interacted with E2F1 and both could mediate 
      EMT process in NSCLC. CONCLUSION: MiR-661 promotes metastasis of NSCLC through 
      RB/E2F1 signaling and EMT events, thus may serves as a negative prognostic factor 
      and possible target for treatment of NSCLC patient.
FAU - Liu, Feiye
AU  - Liu F
AD  - Cancer Center, Traditional Chinese Medicine-Integrated Hospital, Southern medical 
      University, Guangdong, 510315, China.
FAU - Cai, Yanjun
AU  - Cai Y
AD  - Cancer Center, Traditional Chinese Medicine-Integrated Hospital, Southern medical 
      University, Guangdong, 510315, China.
AD  - Center for Geriatrics, General Hospital of Guangzhou Military Command of People's 
      Liberation Army, Guangdong, 510010, China.
FAU - Rong, Xiaoxiang
AU  - Rong X
AD  - Department of Oncology, Nanfang Hospital, Southern medical University, Guangdong, 
      510515, China.
FAU - Chen, Jinzhang
AU  - Chen J
AD  - Department of Oncology, Nanfang Hospital, Southern medical University, Guangdong, 
      510515, China.
FAU - Zheng, Dayong
AU  - Zheng D
AD  - Department of Oncology, Nanfang Hospital, Southern medical University, Guangdong, 
      510515, China.
FAU - Chen, Lu
AU  - Chen L
AD  - Center for Geriatrics, General Hospital of Guangzhou Military Command of People's 
      Liberation Army, Guangdong, 510010, China.
FAU - Zhang, Junyi
AU  - Zhang J
AD  - Cancer Center, Traditional Chinese Medicine-Integrated Hospital, Southern medical 
      University, Guangdong, 510315, China.
FAU - Luo, Rongcheng
AU  - Luo R
AD  - Cancer Center, Traditional Chinese Medicine-Integrated Hospital, Southern medical 
      University, Guangdong, 510315, China.
FAU - Zhao, Peng
AU  - Zhao P
AD  - Department of Medical Oncology, The First Affiliated Hospital, School of 
      Medicine, Zhejiang University, Zhejiang, 310003, China.
FAU - Ruan, Jian
AU  - Ruan J
AD  - Cancer Center, Traditional Chinese Medicine-Integrated Hospital, Southern medical 
      University, Guangdong, 510315, China. software23@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20170717
PL  - England
TA  - Mol Cancer
JT  - Molecular cancer
JID - 101147698
RN  - 0 (E2F1 Transcription Factor)
RN  - 0 (E2F1 protein, human)
RN  - 0 (MIRN661 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (RB1 protein, human)
RN  - 0 (Retinoblastoma Binding Proteins)
RN  - EC 2.3.2.27 (Ubiquitin-Protein Ligases)
SB  - IM
MH  - Aged
MH  - Animals
MH  - Base Sequence
MH  - Carcinoma, Non-Small-Cell Lung/*genetics/*pathology
MH  - Cell Line, Tumor
MH  - E2F1 Transcription Factor/metabolism
MH  - Epithelial-Mesenchymal Transition/genetics
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Lung Neoplasms/*genetics/*pathology
MH  - Male
MH  - Mice, Inbred BALB C
MH  - Mice, Nude
MH  - MicroRNAs/genetics/*metabolism
MH  - Middle Aged
MH  - Neoplasm Invasiveness
MH  - Neoplasm Metastasis
MH  - Prognosis
MH  - Protein Binding
MH  - Retinoblastoma Binding Proteins/*metabolism
MH  - Ubiquitin-Protein Ligases/*metabolism
MH  - Up-Regulation/genetics
PMC - PMC5514511
OTO - NOTNLM
OT  - E2F1
OT  - Metastasis
OT  - Non small cell lung cancer
OT  - RB
OT  - miR-661
COIS- AUTHORS' INFORMATION: Not applicable. ETHICS APPROVAL AND CONSENT TO PARTICIPATE: 
      The study was approved by Research Ethics Committee of Nanfang Hospital and 
      SMUCC. All samples were used according to the ethical guidelines of the 1975 
      Declaration of Helsinki and obtained with the patients' understanding that it 
      might be published. CONSENT FOR PUBLICATION: Not applicable. COMPETING INTERESTS: 
      The authors declare that they have no competing interests. PUBLISHER'S NOTE: 
      Springer Nature remains neutral with regard to jurisdictional claims in published 
      maps and institutional affiliations.
EDAT- 2017/07/19 06:00
MHDA- 2018/04/14 06:00
PMCR- 2017/07/17
CRDT- 2017/07/19 06:00
PHST- 2016/12/20 00:00 [received]
PHST- 2017/07/11 00:00 [accepted]
PHST- 2017/07/19 06:00 [entrez]
PHST- 2017/07/19 06:00 [pubmed]
PHST- 2018/04/14 06:00 [medline]
PHST- 2017/07/17 00:00 [pmc-release]
AID - 10.1186/s12943-017-0698-4 [pii]
AID - 698 [pii]
AID - 10.1186/s12943-017-0698-4 [doi]
PST - epublish
SO  - Mol Cancer. 2017 Jul 17;16(1):122. doi: 10.1186/s12943-017-0698-4.